The effects of allopurinol on immune function in normal BALB/c and SCID mice

International Journal of Immunopharmacology

Volumn 22, Issue 7, 2000, Pages 547-556

  Kato, C ^a   Sato, K ^a   Wakabayashi, A ^b   Eishi, Y ^b  

^a JAPAN WOMEN'S UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Allopurinol (AL); Immune function; Ovalbumin (OVA); Severe combined immunodeficient (SCID); Xanthinoxidase (XO)

Indexed keywords

ALLOPURINOL; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; OVALBUMIN; URIC ACID; XANTHINE OXIDASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CELL TRANSFER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURINE METABOLISM; STEM CELL; STRAIN DIFFERENCE; T LYMPHOCYTE;

ALLOPURINOL; ANIMALS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; MICE, SCID; OVALBUMIN; URIC ACID;

EID: 0034237122     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00018-7     Document Type: Article

References (25)

1. Hayward A.R. Resistance of pokeweed mitogen-stimulated B cells to inhibitiion by deoxyadenosine. Clin. Exp. Immunol. 41:1980;141-149.
2. Goday A., Simmonds H.A., Morris G.S., Fairbanks L.D. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency. Biochem. Pharmacol. 34:1985;3561-3569.
3. Zegers B.J., Stoop J.W., Staal G.E., Wadman S.K. An approach to the restration of T cell function in a purine nucleoside phosphorylase deficient patient. Civa Found Symp. 68:1978;231-253.
4. Zabay J.M., de LaConcha E.G., Ludena C., Lozano C., Pascual-Salcedo D., Bootello A., Gonzalezporque P. B cell hyperactivity and abnormalities in T cell marlers and immunoregulatory function in a patient with nucleoside phosphorylase deficiency. Lin. Exp. Immunol. 50:1982;510-516.
5. Albert D., Bluestein H.G., Willis R.C., Nette K., Seegmiller J.E. The mechanism of inhibitiion and "reversal" of mitogen-induced lymphocyte activation in a model of purine-nucleoside phosphorylase deficiency. Cell Immunol. 86:1984;501-509.
6. Nelson D.M., Butters K.A., Markert M.L., Reinsmoen N.L., McIvor R.S. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression. J. Immunol. 154:1995;3006-3014.
7. Carpenter P.A., Ziegler J.B., Vowels M.R. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation. Bone Marrow Transplant. 17:1996;121-124.
8. Webster A.D., Rowe M., Johnson S.M. Ecto 5′-nucleotidase deficiency in primary hypogammaglobulinaemia. Ciba Found Symp. 68:1978;135-151.
9. Edwards N.L., Cassidy J.T., Fox I.H. Lymphocyte 5′-nucleotidase deficiency: clinical and metabolic characteristics of the associated hypogammaglobulinemia. Adv. Exp. Med. Biol. 122B:1979;315-320.
10. Tisman G., Wu S.J. Allopurinol modulation of high-dose fluouracil toxicity. Lancet. 1:1979;1353-1354.
11. Schwartz P.M., Dunigan J.M., Marsh J.C., Handschumacher R.E. Allopurinol modification of the toxicity and antitumor activity of 5-fluuorouracil. Cancer Res. 40:(6):1980;1885-1889.
12. Clark P.I., Slevin M.L. Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. Eur. J. Surg. Oncol. 11:(3):1985;267-268.
13. Niehorster M., Schonharting M., Wendel A. A novel xanthine derivative counteracting in vivo tumor necrosis factor alpha toxicity in mice. Circ. Shock. 37:1992;270-273.
14. Masson E., Synold T.W., Relling M.V., Schuetz J.D., Sandlund J.T., et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukimia. 10:(1):1996;56-60.
15. Kurashige S., Akuzawa Y., Mitsuhashi S. Purine metabolic enzymes in lymphocytes. Part IV: Effects of enzyme inhibitors and enzyme substrates on the blastogenic responses of human lymphocytes. Scand. J. Immunol. 22:1985;1-7.
16. Luis H., Toledo-Pereyra Rose H. A study of the immunosupressive effect of allopurinol. Immunological Communications. 9:(1):1980;7-11.
17. Olah T., Regely K., Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;96-99.
18. Branden G.L., Warzynski M.J., Golightly M., Ballow M. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin. Immunol. and Immunopatho. 70:(2):1994;145-151.
19. Nishida K., Ohta Y., Kobayashi T., Ishiguro I. Involvement of the xanthine-xanthine oxidase system and neutrophils in the development of acute gastric mucosal lesions in rats with water immersion restraint stress. Digestion. 58:(4):1997;340-351.
20. Schimpl G., Pesendorfer P., Steinwender G., Feierl G., Ratschek M., et al. Allopurinol reduces bacterial translocation, intestinal mucosal lipid peroxidation, and neutrophil-derived myeloperoxidase activity in chronic portal hypertensive and common bile duct-ligated growing rats. Pediatr. Res. 40:(3):1996;422-428.
21. Demling R.H., LaLonde C. Early postburn lipid peroxidation: effect of ibuprofen and allopurinol. Surgery. 107:(1):1990;85-93.
22. Nishida Y., Okudaira K., Tanimoto K., Akaoka I. The differences in purine metabolism between T and B lymphocytes. Exp. Hematol. 8:1980;593-598.
23. Renouf J.A., Thong Y.H., Chalmers A.H. Activities of purine metabolising enzymes in lymphocytes of neonates and young children: correlates with immune function. Immunol. Letters. 15:1987;161-166.
24. Allison A.C., Hovi T., Watts R.W., Webster A.D. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp. 48:1977;207-224.
25. Matuura G., Goto H., Kezuka T., Yamakawa N., Usui M. Suppression of experimental autoimmune uveoretinitis with a combination of cyclosporin and allopurinol. Nippon Ganka Gakkai Zasshi. 103:(1):1999;26-33.